Merck & Co., Inc. logo

Merck & Co., Inc. (MRK)

Market Closed
25 Feb, 20:00
$
122. 46
-1.47
-1.19%
$
305.38B Market Cap
58.39 P/E Ratio
3.4% Div Yield
7,737,808 Volume
1.46 Eps
$ 123.93
Previous Close
Day Range
122.27 125.14
Year Range
73.31 125.14
Want to track MRK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MRK earnings report is expected in 56 days (23 Apr 2026)
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study

MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study

The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.

Zacks | 1 year ago
Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)

Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)

Merck & Co. Inc. (NYSE:MRK ) Citi's 2024 Global Healthcare Conference December 5, 2024 8:00 AM ET Company Participants Rob Davis - Chairman and CEO Eliav Barr - Senior VP, Head of Global Clinical Development and CMO Conference Call Participants Geoff Meacham - Citi Geoff Meacham Welcome to the morning session of the First Annual Citi Global Healthcare Conference. My name is Geoff Meacham.

Seekingalpha | 1 year ago
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 year ago
Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)

Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK ) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Peter Dannenbaum - SVP, IR Eliav Barr - Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay. Excellent.

Seekingalpha | 1 year ago
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study

Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study

MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.

Zacks | 1 year ago
Why Is Merck Stock Trading Higher On Monday?

Why Is Merck Stock Trading Higher On Monday?

On Monday, Merck & Co Inc MRK revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality.

Benzinga | 1 year ago
Merck's therapy for rare lung condition shown to help reduce risk of death in study

Merck's therapy for rare lung condition shown to help reduce risk of death in study

Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition which causes high blood pressure in the lungs, months after it secured approval in the United States.

Reuters | 1 year ago
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value

Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value

In today's market, many investors are distracted by hype. But the real value lies in stocks that provide strong, consistent dividend yields without the noise. Instead of chasing the latest trends, focusing on high-yield dividend stocks that are undervalued is a smart strategy for building wealth over time. Two of my picks offer both deep value and high yields, making them standout opportunities for any dividend-focused portfolio.

Seekingalpha | 1 year ago
Merck Stock Trades Near 52-Week Low: What's Next for Investors?

Merck Stock Trades Near 52-Week Low: What's Next for Investors?

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Zacks | 1 year ago
Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference

Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference

Merck & Co., Inc. (NYSE:MRK ) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET Corporate Participants Joe Romanelli - President, Human Health International Marjorie Green - SVP and Head of Oncology, Global Clinical Development, Merck Research Laboratories Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone Day 3. We're at the end of it.

Seekingalpha | 1 year ago
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

Fool | 1 year ago
Loading...
Load More